InformAI, Inc. Receives $1M in NIH Grant Funding for Innovative Use of AI in Organ Transplantation

InformAI, Inc. received $1 million in grant funding for the second year of the National Institutes of Health (NIH) Fast-Track grant (Project # 1R44HL172564-01).

HOUSTON, TX, UNITED STATES, September 24, 2026 /EINPresswire.com/ -- InformAI, Inc. received $1 million in grant funding for the second year of the National Institutes of Health (NIH) Fast-Track grant (Project # 1R44HL172564-01). The funding supports TransplantAI, which addresses the pressing issues of organ scarcity, organ discard, and donor/recipient matching for heart, lung, kidney, and liver organs. The NIH Fast-Track award expedites funding for Small Business Innovation Research (SBIR) projects that are scientifically meritorious and have strong commercialization potential. In 2025, more than 49,000 organ transplants were performed in the United States, and more than 100,000 people are currently waiting for an organ transplant.

> At InformAI, we are relentlessly focused on delivering high-quality AI clinical solutions, including TransplantAI, which improves organ transplant patient outcomes by optimizing donor-organ matching.”
>
> *Jim Havelka, Founder & CEO*

TransplantAI leverages patient clinical and imaging data to enhance clinical decision support for organ transplant centers and organ procurement organizations. Using advanced AI algorithms, TransplantAI has demonstrated superior predictive accuracy for organ transplant outcomes compared with existing clinical decision support tools. Dr. Abbas Rana, Associate Professor of Surgery at Baylor College of Medicine and clinical principal investigator, states: “There is an urgent need for improved, integrated predictive clinical insights in solid organ transplantation, including real-time assessment of waitlist mortality and the likelihood of successful post-transplant outcomes. These supporting clinical insights are essential for healthcare teams to make informed decisions, particularly in complex cases where expanded criteria allocation decisions are under consideration.”

Jim Havelka, founder and CEO of InformAI, states, "At InformAI, we are relentlessly focused on delivering high-quality AI clinical solutions, including TransplantAI, which improves organ transplant patient outcomes by optimizing donor-organ matching for patients on heart, lung, kidney, and liver waitlists."

About InformAI: InformAI is a technology company based in the Texas Medical Center, dedicated to advancing healthcare through AI-enabled clinical solutions, with a focus on surgical analytics and oncology.

Research reported in this press release is supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health under award number R44HL172564.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Jackie Coleman
InformAI, Inc.
+1 281-670-7085
email us here
Visit us on social media:
LinkedIn
X

This press release can be viewed online at: https://www.einpresswire.com/article/944971627

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.